目的 探讨胱抑素C在131I治疗甲亢中的临床应用价值。方法 选择2011年2月至2012年10月在我院131I治疗的43例甲亢患者和40例健康者（对照组）进行甲状腺激素、血清胱抑素C(CysC)水平的比较；并观察甲亢患者131I治疗后3个月、6个月与治疗前的甲状腺激素、血清胱抑素C(CysC)与血清肌酐(Cr)水平变化。结果 甲亢患者血清CysC水平增高，随着甲亢患者131I治疗后甲状腺激素水平的恢复，血清CysC水平降低(P<0.05)。 结论 血清胱抑素C(CysC)可以作为甲亢的辅助检测项目和131I治疗后疗效判定的辅助诊治指标。

objective To investigate the clinical value of cystatin C in 131I treatment of patients with hyperthyroidism. Methods The thyroid hormone level and serum level of Cys C and Cr in 43 patients with hyperthyroidism before and after 3 and 6 months of 131I treatment and in 40 healthy controls were determined. Results The serum Cys C levels in patients with hypothyroidism were higher than that of healthy controls. The thyroid hormone level in patients with hypothyroidism were back to normal and serum Cys C levels were decreased after 131I treatment (P<0.05)．Conclusion Cystatin C can be the auxiliary diagnostic examination item of hyperthyroidism and could be acted as an auxiliary diagnosis index of efficacy evaluation after 131I treatment.